This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (eHealth) (538) Cancer and Clinical Trials (19)

Published on in Vol 7, No 7 (2018): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/11191, first published .
Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Authors of this article:

Isao Hara1 Author Orcid Image ;   Shimpei Yamashita1 Author Orcid Image ;   Satoshi Nishizawa1 Author Orcid Image ;   Kazuro Kikkawa1 Author Orcid Image ;   Toshio Shimokawa2 Author Orcid Image ;   Yasuo Kohjimoto1 Author Orcid Image
Article Authors Cited by (7) Tweetations (1) Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.